Cariprazine hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Cariprazine hydrochloride Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
88
Registered trials
40
Result records
6
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Cariprazine hydrochloride can convert its Small molecule drug profile and 5-HT1A receptor x 5-HT2A receptor x D2 receptor x D3 receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Cariprazine hydrochloride (query alias: cariprazine) |
|---|---|
| Modality / target | Small molecule drug; 5-HT1A receptor x 5-HT2A receptor x D2 receptor x D3 receptor; 5-HT1A receptor agonists, 5-HT2A receptor antagonists, D2 receptor partial agonists |
| Highest global status | Approved |
| Originator | Chemical Works of Gedeon Richter Plc |
| Active developers | Chemical Works of Gedeon Richter Plc, Qilu Pharmaceutical Co., Ltd., AbbVie, Inc. |
The MCP disease footprint includes Depressive Disorder, Major, Bipolar and Related Disorders, Bipolar Disorder. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07266545 | Phase 4 | Recruiting | 120 | Change in Montgomery-Åsberg Depression Rating Scale (MADRS) score |
| NCT07185815 | Phase 1/2 | Recruiting | 24 | Safety, rate of adverse events (AEs) |
| NCT07484204 | Phase 1 | Not yet recruiting | 48 | Pharmacokinetic Parameter |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Efficacy of Adjunctive Cariprazine on Anxiety Symptoms in Patients With Major Depressive Disorder
Phase 3; n=751; evaluation: Positive. Reported fields: -; HAM-A total scores(6-week, 1.5 mg/d) = -1.3 Point ( -2.5 to -0.1); -
Gedeon Richter: an effective treatment for female schizophrenia patients
Not Applicable; n=116; evaluation: Positive. Reported fields: SAND(change from baseline) = There was a significant change from baseline in women to week 16 in the SAND scores: negative symptoms decreased by 6.2, positive symptoms decreased with 1.0, which is a remarkable, combined 7.2 drop.
A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety and Tolerability of Cariprazine in a Dose-reduction Paradigm in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features
Phase 3; n=901; evaluation: not stated. Reported fields: 25% percentile(Median) = NA days (95% Confidence Interval, 220.0 - NA); 25% percentile(Median) = NA days (95% Confidence Interval, 224.0 - NA); -
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Cariprazine hydrochloride addresses Depressive Disorder, Major, Bipolar and Related Disorders, Bipolar Disorder. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 6 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-08-07 | Zhejiang Jingxin Pharmaceutical Signs Patent Licensing Agreement with Gedeon Richter Plc. | Approved | US$0.6M milestones |
| 2025-04-01 | Pharmanovia acquires exclusive rights to novel antipsychotic treatment | Approved | Financial terms not disclosed |
| 2022-03-11 | AbbVie and Gedeon collaborate to create and market dopamine receptor modulators for neuropsychiatric disorders. | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Cariprazine oral soluble film and preparation method thereof”. The milestone feed surfaced a patent-application signal described as “Cariprazine hydrochloride pharmaceutical composition”. The milestone feed surfaced a patent-application signal described as “Long-Acting Injectable (LAI) Composition of Cariprazine”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
